Could new drugs for early Alzheimer’s really signal the end of dementia? These women say ‘breakthrough’ medicines have halted their mental decline. But do side-effects – and cost – outweigh the benefits…

Daily Mail, May 30, 2023: The Daily Mail reports on new Alzheimer’s drugs that are approved in the US but not in the UK. Dr. Zuckerman & other experts ask: Are they worth the costs or the risks? Patients want access but do these drugs really work? Mild cognitive impairment can change daily without treatment – we all have good days and bad days.

Read More »

FDA advisers recommend accelerated approval of a Sarepta gene therapy

Boston Globe, May 12, 2023: FDA advisers recommended accelerated approval of Sarepta gene therapy for Duchenne Muscular Dystrophy, despite questionable results and worrisome risks. We testified that lowering FDA standards harms all families, and that Duchenne patients deserve free access to affordable treatments until drugs are proven to work.

Read More »